DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of May 22, 2026, DNTH stock price declined to $86.48 with 454,455 million shares trading.

DNTH has a beta of -0.12, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.

DNTH has a market cap of $4.73 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $463,000 in Revenue and -$.85 earnings per share. This beat revenue expectation by $66,048 and exceeded earnings estimates by $.27.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

DNTH has outperformed the market in the last year with a return of +371.0%, while the SPY ETF gained +29.1%. In the last 3 month period, DNTH beat the market returning +74.5%, while SPY returned +8.4%. However, in the most recent 2 weeks DNTH has underperformed the stock market by returning -0.3%, while SPY returned +1.1%.

DNTH support price is $86.58 and resistance is $92.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.